作者
Ching-Hua Lu, Corrie Macdonald-Wallis, Elizabeth Gray, Neil Pearce, Axel Petzold, Niklas Norgren, Gavin Giovannoni, Pietro Fratta, Katie Sidle, Mark Fish, Richard Orrell, Robin Howard, Kevin Talbot, Linda Greensmith, Jens Kuhle, Martin R Turner, Andrea Malaspina
发表日期
2015/6/2
期刊
Neurology
卷号
84
期号
22
页码范围
2247-2257
出版商
Lippincott Williams & Wilkins
简介
Objective
To test blood and CSF neurofilament light chain (NfL) levels in relation to disease progression and survival in amyotrophic lateral sclerosis (ALS).
Methods
Using an electrochemiluminescence immunoassay, NfL levels were measured in samples from 2 cohorts of patients with sporadic ALS and healthy controls, recruited in London (ALS/control, plasma: n = 103/42) and Oxford (ALS/control, serum: n = 64/36; paired CSF: n = 38/20). NfL levels in patients were measured at regular intervals for up to 3 years. Change in ALS Functional Rating Scale–Revised score was used to assess disease progression. Survival was evaluated using Cox regression and Kaplan–Meier analysis.
Results
CSF, serum, and plasma NfL discriminated patients with ALS from healthy controls with high sensitivity (97%, 89%, 90%, respectively) and specificity (95%, 75%, 71%, respectively). CSF NfL was highly correlated with serum …
学术搜索中的文章
CH Lu, C Macdonald-Wallis, E Gray, N Pearce… - Neurology, 2015